Shield Therapeutics plc (STX.L) LSE

Currency In GBp

AD

Valuation

Market Cap86.81M
Enterprise Value105.33M
P/E Ratio-6.75
PEG Ratio-0.07
Price/Sales Ratio1.21
Price/Book Ratio-4.13
Enterprise/Revenue1.49
Enterprise/EBITDA-26.66

Fiscal Year

Fiscal YearDecember 31, 2025
Most Recent QuarterJune 30, 2026

Profitability

Profit Margin-0.18
Operating Margin-0.07
AD

Management Effectiveness

Return On Assets-0.19
Return On Equity0.65

Income Statement

Revenue50.74M
Revenue/Share0.05
Gross Profit22.38M
EBITDA-9.16M
Net Income-18.03M
Diluted EPS-0.02

Balance Sheet

Total Cash8.39M
Total Cash/Share0.01
Total Debt25.03M
Total Debt/Equity-1.46
Current Ratio0.75
Book Value Per Share-0.02

Price History

52-Week Change-39.83
52-Week High12.5
52-Week Low3.7
Moving Average 50 Days5.56
Moving Average 200 Days8.12

Statistics

Average Volume2.18M
Shares Outstanding1.07B
% Held by InstitutionsN/A

Dividend And Splits

Trailing Annual Dividend Rate0
Trailing Annual Dividend Yield0
Payout Ratio0
Last Split Factor1029:1000
Last Split DateDecember 16, 2022
AD